Pneumococcal vaccine conjugate - Merck & Co

Drug Profile

Pneumococcal vaccine conjugate - Merck & Co

Latest Information Update: 12 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Pneumococcal vaccines; Polysaccharides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pneumococcal infections

Most Recent Events

  • 12 Feb 2008 Discontinued - Clinical-Phase-Unknown for Pneumococcal infections in Israel (IM)
  • 12 Feb 2008 Discontinued - Phase-II for Pneumococcal infections in Finland (IM)
  • 12 Feb 2008 Discontinued - Phase-III for Pneumococcal infections in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top